E3A Healthcare debut it’s non-invasive Bilirubin meter at CIIE 2022

On November 10, 2022, the Fifth China International Import Expo, sponsored by the Ministry of Commerce and the Shanghai Municipal People's Government, and organized by the China International Import Expo Bureau and the National Convention and Exhibition Center (Shanghai), successfully concluded in Shanghai!

A total of 145 countries, regions and international organizations participated in this year's CIIE. 284 of the world's top 500 companies and leading companies in the industry showed their products and displayed 438 representative new products, new technologies and new services, which attracted global attention.

Yishan Medical made a stunning appearance at the CIIE with its self-developed new generation of intelligent neonatal percutaneous jaundice!

Yishan Medical New Product Launch Conference

At the new product launch conference, experts from all walks of life, media matrix, distributors, consumers and other heavyweight guests gathered together to witness the important moment of Yishan Medical's new product release! Mr. Chen Hongyuan, CMO of Yishan Medical, grandly introduced the new product independently developed and produced by the Yishan Medical team and certified by the National Medical Products Administration (NMPA) - [Intelligent Neonatal Transdermal Jaundice Instrument YSJ20].

Yishan medical transdermal jaundice instrument adopts the patented optical detection technology developed exclusively, breaking the high price threshold caused by foreign technology monopoly. The body is small and light, easy to operate, and greatly improves the portability and accessibility of the product. It is very suitable for medical institutions to establish the service capacity of primary jaundice monitoring, popularize primary medical services for neonatal jaundice, improve the accessibility of jaundice detection, and ensure the quality of medical services.

At the same time, combined with IoT and AI big data technology, Yishan Medical grandly launched the "Smart Maternal and Infant Health Management Platform" software service, aiming at the limited primary medical resources currently facing our country, and the lack of underlying technology of the Internet platform for maternity and child specialties in the process of hospital digitalization, which led to the epidemic It is impossible to realize the pain points of doctors and patients such as online diagnosis and remote return visit in the environment, and provide a comprehensive solution for the remote health management of newborns through the complete intercommunication of information through "hardware home monitoring + software doctor-patient interconnection".

The release of this new product has aroused people's attention and further attention to newborn health, remote smart medical technology and family health care in the post-epidemic era. Through reports from hundreds of domestic and foreign media, we quickly received many inquiries and launched our products. The popularity has accelerated our market layout.

CCTV direct hit, much attention

As a cutting-edge medical technology company that focuses on the research and development of intelligent maternal and child medical devices and is committed to providing comprehensive maternal and child health management services, Yishan Medical CMO Mr. Chen Hongyuan shared the company's development history and vision with everyone on the stage, and gave everyone The highlights and advantages of the new jaundice instrument are explained in detail. The press conference was broadcast live by CCTV and attracted worldwide attention.

Yishan Medical-The whole process of the new product launch conference of the 5th CIIE

In the future, Yishan Medical will join hands with many domestic medical institutions, relying on its strong scientific research strength and product advantages, to accelerate the digital transformation of traditional hospitals, cooperate to build a maternal and infant specialist service system, popularize primary medical services for neonatal health, and improve maternal and infant medical services Quality, and go all out to protect the healthy growth of more newborns.

Previous
Previous

E3A Healthcare wins 2022 Global University Startup World Cup!

Next
Next

E3A Healthcare wins the runner-up biotech group winner at SLINGSHOT 2022 Grand Finals!